Deep Vein Thrombosis Clinical Trial
Official title:
Phase II Study on the Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer
The primary hypothesis of this study is that occult catheter-related DVT in children with cancer is common and directly contributes to development of serious catheter complications, specifically bacteremia/fungemia and/or recurrent occlusion of the catheter tip. Accordingly, anticoagulant treatment of clinically silent (occult) DVT will reduce rates of catheter-related infection and occlusion, delays in therapy and need for catheter replacement.
This is a two-part study with an initial diagnosis component followed by a treatment
component. The number of subjects to be consented for the diagnosis component is 350, and 50
for the treatment portion (25 on the observation arm, and 25 for enoxaparin treatment).
Study Procedures:
Patients diagnosed with cancer at the Center for Cancer and Blood Disorders will have a
catheter inserted for cancer related treatment. After insertion, eligible patients who
provide consent will be enrolled in the diagnosis component of the study. The principal
investigator and research team will monitor for catheter complications (occlusion and
bacteremia/fungemia). After two complications, participants will be screened for occult
central venous catheter (CVC)-related DVT by contrast venography, ultrasonography, or
magnetic resonance venography. If DVT is not diagnosed, participant will go off the study. If
DVT is diagnosed, participant will be asked to consent to enroll in the treatment study.
After enrollment, participant is randomized between the two arms of observation and
enoxaparin treatment. After 6 weeks, patients will have another image; this represents the
end of treatment period. After the follow-up imaging, patients will be monitored for 10 weeks
to obtain primary outcomes. Once a primary outcome (progression to symptomatic DVT or
pulmonary embolism (PE), blood stream infection or catheter removal) is achieved the
participants can be treated with anticoagulation again if necessary, but primary oncologist
will determine treatment.
Analysis:
The hypothesis is that the enoxaparin treatment group will have a median adverse catheter
event free survival time of 12 weeks versus 4 weeks for the control group with a hazard
ration of 0.4. A total sample size of 50 (25 in each arm) will detect such a difference with
90% power at an α=0.05. If there is a drop out rate of 10% in each arm, a difference can
still be detected with 80% power.
Approximately 200 to 250 patients are diagnosed with cancer each year at Children's Medical
Center Dallas, and based on prior institutional experience, two-thirds will have catheters
inserted to facilitate chemotherapy. However, one-quarter of these patients have brain tumors
and are not eligible due to the potential increased risk of intracranial hemorrhage with
anticoagulation. There will be 100 patients each year who are at risk for CVC-related DVT.
Based on previous studies, up to 50% of patients should develop occult DVT; however, only 35%
of patients will likely be screened with radiographic imaging. Approximately 17 patients a
year enrolled in the diagnosis study may be diagnosed with DVT and eligible for
randomization. Therefore, total enrollment will be completed in approximately 3 years with an
additional 4 months necessary to complete the follow-up period.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05003843 -
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
|
N/A | |
| Recruiting |
NCT03937947 -
Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
|
||
| Withdrawn |
NCT04136561 -
Novel Strategy to Encourage Early Removal of Central Venous Catheters
|
N/A | |
| Completed |
NCT03420625 -
Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices
|
N/A | |
| Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
| Completed |
NCT02555111 -
Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
|
Phase 3 | |
| Terminated |
NCT02469376 -
Evaluation of a New Imagingtechnologie for Thrombosis
|
Phase 1 | |
| Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
| Completed |
NCT02037607 -
Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures
|
N/A | |
| Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
| Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
| Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
| Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
| Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 | |
| Completed |
NCT00264277 -
D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism
|
Phase 4 | |
| Completed |
NCT00365950 -
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
|
Phase 4 | |
| Completed |
NCT00182403 -
Fixed Dose Heparin Study
|
Phase 3 | |
| Completed |
NCT03682419 -
Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
|
N/A | |
| Not yet recruiting |
NCT04981327 -
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
|
Phase 3 | |
| Recruiting |
NCT03240120 -
A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
|
Phase 3 |